(Press-News.org) Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).
According to the results, there is an indication of considerable added benefit in comparison with "best supportive care" (BSC) because ruxolitinib is better at relieving symptoms. Moreover, a hint of an added benefit with regard to survival can be derived from the dossier. Its extent is non-quantifiable, however.
Bone marrow is replaced by connective tissue
Myelofibrosis is a rare disease of the bone marrow, in which the bone marrow is replaced by connective tissue. As a consequence of this so-called fibrosis, the bone marrow is no longer able to produce enough blood cells. Sometimes the spleen or the liver takes over some of the blood production. Then these organs enlarge and can cause abdominal discomfort and pain. The typical symptoms also include feeling of fullness, night sweats and itching. Some patients with myelofibrosis develop leukaemia.
Stem cell transplantation is currently the only option to cure myelofibrosis. The drug ruxolitinib aims to relieve the symptoms of myelofibrosis.
G-BA specifies appropriate comparator therapy
Ruxolitinib is an option for patients with so-called primary or secondary myelofibrosis whose spleen is already enlarged (splenomegaly) or who have other disease-related symptoms.
The G-BA specified "best supportive care" (BSC) as appropriate comparator therapy. BSC means a therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve quality of life. This also includes adequate pain therapy.
Relevant study ongoing until 2015
In its assessment, IQWiG could include one randomized controlled trial (RCT) conducted in 89 centres in Australia, Canada and the United States (COMFORT-I). The 309 patients in total were either treated with ruxolitinib plus BSC or with placebo plus BSC.
The first analysis (primary analysis) was conducted in 2010 after all patients had been treated for 24 weeks and half of them for 36 weeks. Then all participants were unblinded and could switch to the ruxolitinib arm of the study. If their spleen volume had increased by more than 25%, they could also switch earlier. A 3-year analysis was conducted in 2013. The study was prolonged to 2015, however, to obtain long-term data.
Overall survival: results not consistently significant
With regard to survival time, the differences between the two treatment groups were not statistically significant in favour of ruxolitinib in all of the four analysis dates. Because of the high proportion of patients who switched treatment, the survival advantage of ruxolitinib is rather underestimated. Overall, IQWiG therefore considers there to be a hint of an added benefit. The extent of this added benefit is unclear, however.
Morbidity: fewer symptoms in ruxolitinib group
A disease-specific questionnaire (MFSAF v2.0) was used to record symptoms in the COMFORT-I study. This instrument comprises myelofibrosis symptoms and aggregates them to one value (total symptom score, [TSS]). In the ruxolitinib + BSC group, considerably more patients than in the placebo + BSC group reported that their symptoms have improved.
Regarding the occurrence of leukaemia (leukaemic transformation), a typical late complication, there were no differences between the two treatment groups in the study.
For the outcome "morbidity", IQWiG therefore recognizes an indication of an added benefit with the extent "considerable".
No evaluable results on quality of life
The dossier contained no evaluable data on quality of life. Quality of life was recorded in the study using an instrument developed for cancer (EORTC QLQ-C30). However, different proportions of participants in the two treatment groups remained unconsidered in the analysis. As the difference of the missing values was more than 20 percentage points, no reliable conclusions can be derived from the results.
For the same reason, the data on symptoms that were also recorded with EORTC QLQ-C30 are also not evaluable.
Only limited conclusions on side effects possible
Only limited conclusions can be drawn on side effects. This is mainly due to the fact that typical symptoms of myelofibrosis, such as night sweats, were also recorded as "adverse events". This means that it remains unclear whether these were side effects of the drug or symptoms of the underlying condition. Such events that are not clearly attributable allow no informative conclusions on side effects.
Although greater harm from ruxolitinib can also not be ruled out completely, the available data contain no signs of harm of a magnitude that might justify downgrading the added benefit as a whole.
Hence the positive effects with regard to symptom relief (indication) and prolongation of life (hint) remain. Overall, IQWiG therefore regards there to be an indication of considerable added benefit of ruxolitinib in comparison with BSC.
First orphan drug with a turnover of over 50 million euros
Ruxolitinib has the status "orphan drug". According to §35a (1), Sentence 10, Social Code Book V [SGB V]), the medical added benefit is regarded as proven if a drug has been approved, as long as the yearly turnover in the statutory health insurance (SHI) funds does not exceed 50 million euros. In this case, the G-BA only has to determine the extent of added benefit. The G-BA made this decision on ruxolitinib in March 2013.
In 2013, ruxolitinib was the first drug for rare diseases to exceed the 50 million euro threshold. The G-BA therefore requested the drug manufacturer to submit proof of the added benefit of ruxolitinib in comparison with the appropriate comparator therapy in a dossier, and commissioned IQWiG with the assessment.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G‑BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on ruxolitinib.
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a SGB V and specific German-language information on the assessment of ruxolitinib.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealthonline.org)
If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.
Ruxolitinib for myelofibrosis: Indication of considerable added benefit
Advantages in symptoms and survival time in comparison with 'best supportive care'
2014-08-19
ELSE PRESS RELEASES FROM THIS DATE:
College education not always about what you have, but how you use it
2014-08-19
Students who have books and computers at home, who take extramural cultural classes, and whose parents give advice and take part in school activities are most likely to enroll for a four-year college degree. Also, more American black students – irrespective of their class or background – will set off on this education path than their white counterparts. So says David Merolla of Wayne State University and Omari Jackson of Colby-Sawyer College in the US, in Springer's journal Race and Social Problems. Merolla and Jackson studied class and race differences in college enrollment, ...
Organic photovoltaic cells of the future
2014-08-19
WASHINGTON D.C., Aug. 19, 2014 – Organic photovoltaic cells -- a type of solar cell that uses polymeric materials to capture sunlight -- show tremendous promise as energy conversion devices, thanks to key attributes such as flexibility and low-cost production.
But one giant hurdle holding back organic photovoltaic technologies have been the complexity of their power conversion processes, which involve separate charge formation and transport processes.
To maneuver around this problem, a team of researchers in Japan has developed a method to determine the absolute value ...
Love makes sex better for most women
2014-08-19
Love and commitment can make sex physically more satisfying for many women, according to a Penn State Abington sociologist.
In a series of interviews, heterosexual women between the ages of 20 and 68 and from a range of backgrounds said that they believed love was necessary for maximum satisfaction in both sexual relationships and marriage. The benefits of being in love with a sexual partner are more than just emotional. Most of the women in the study said that love made sex physically more pleasurable.
"Women said that they connected love with sex and that love actually ...
Life on Mars? Implications of a newly discovered mineral-rich structure
2014-08-19
New Rochelle, August 19, 2014—A new ovoid structure discovered in the Nakhla Martian meteorite is made of nanocrystalline iron-rich clay, contains a variety of minerals, and shows evidence of undergoing a past shock event from impact, with resulting melting of the permafrost and mixing of surface and subsurface fluids. Based on the results of a broad range of analytical studies to determine the origin of this new structure, scientists present the competing hypotheses for how this ovoid formed, point to the most likely conclusion, and discuss how these findings impact the ...
Women will benefit from the Affordable Care Act's contraceptive coverage
2014-08-19
Women could benefit greatly from the Affordable Care Act's mandate for contraceptive coverage, according to Penn State College of Medicine researchers.
The Affordable Care Act requires private insurance plans -- except those grandfathered or exempted due to employers' religious beliefs -- to provide women with access to all FDA-approved contraceptive methods without cost-sharing. This first-dollar coverage "has the potential to dramatically shift contraceptive use patterns, to reduce the U.S. unintended pregnancy rate ... and to improve the health of women and families," ...
Evolution of marine crocodilians constrained by ocean temperatures
2014-08-19
The ancestors of today's crocodiles colonised the seas during warm phases and became extinct during cold phases, according to a new Anglo-French study which establishes a link between marine crocodilian diversity and the evolution of sea temperature over a period of more than 140 million years.
The research, led by Dr Jeremy Martin from the Université de Lyon, France and formerly from the University of Bristol, UK is published this week in Nature Communications.
Today, crocodiles are 'cold-blooded' animals that mainly live in fresh waters but two notable exceptions, ...
Electrical engineers take major step toward optical computing
2014-08-19
Edmonton—The invention of fibre optics revolutionized the way we share information, allowing us to transmit data at volumes and speeds we'd only previously dreamed of.
Now, electrical engineering researchers at the University of Alberta in Edmonton, Alberta, Canada are breaking another barrier, designing nano-optical cables small enough to replace the copper wiring on computer chips.
This could result in radical increases in computing speeds and reduced energy use by electronic devices.
"We're already transmitting data from continent to continent using fibre optics, ...
NASA sees Tropical Storm Karina losing its punch
2014-08-19
Tropical Storm Karina continues to weaken in the Eastern Pacific over open waters, and NASA data shows there's not much punch left in the storm.
NASA's Tropical Rainfall Measuring Mission or TRMM satellite can measure the rate of rainfall from its orbit in space and when it passed over Tropical Storm Karina in the Eastern Pacific it saw an isolated area of heavy rain remaining in the storm.
Tropical Storm Karina weakened during the overnight hours and by Tuesday, August 19, maximum sustained winds had decreased to near 60 mph (95 kph). When TRMM passed overhead at 03:04 ...
Secrets of how worms wriggle uncovered
2014-08-19
LIVERPOOL, UK – 19 August 2014: An engineer at the University of Liverpool has found how worms move around, despite not having a brain to communicate with the body.
Dr Paolo Paoletti, alongside his colleague at Harvard, Professor L Mahadevan, has developed a mathematical model for earthworms and insect larvae which challenges the traditional view of how these soft bodied animals get around.
The most widely accepted model is that of the central pattern generator (CPG) which states that the central brain of these creatures generates rhythmic contraction and extension ...
NASA sees Depression 12-E become Tropical Storm Lowell
2014-08-19
In less than 24 hours after Tropical Depression 12-E was born in the eastern Pacific Ocean it strengthened into Tropical Storm Lowell. NOAA's GOES-West and NASA's Aqua satellite captured infrared images of the massive storm as it continues to strengthen.
On August 18 at 21:11 UTC (5:11 p.m. EDT), NASA's Aqua satellite passed over the Eastern Pacific and the Atmospheric Infrared Sounder (AIRS) instrument gathered infrared data on Lowell's clouds and sea surface temperatures. The AIRS infrared data showed that powerful thunderstorms stretching high into the troposphere ...
LAST 30 PRESS RELEASES:
New strategies to enhance chiral optical signals unveiled
Cambridge research uncovers powerful virtual reality treatment for speech anxiety
2025 Gut Microbiota for Health World Summit to spotlight groundbreaking research
International survey finds that support for climate interventions is tied to being hopeful and worried about climate change
Cambridge scientist launches free VR platform that eliminates the fear of public speaking
Open-Source AI matches top proprietary model in solving tough medical cases
Good fences make good neighbors (with carnivores)
NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer
Introducing our new cohort of AGA Future Leaders
Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help
Engineering excellence: Engineers with ONR ties elected to renowned scientific academy
New CRISPR-based diagnostic test detects pathogens in blood without amplification
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer
Growing solar: Optimizing agrivoltaic systems for crops and clean energy
Scientists discover how to reactivate cancer’s molecular “kill switch”
YouTube influencers: gaming’s best friend or worst enemy?
uOttawa scientists use light to unlock secret of atoms
NJIT mathematician to help map Earth's last frontier with Navy grant
NASA atmospheric wave-studying mission releases data from first 3,000 orbits
‘Microlightning’ in water droplets may have sparked life on Earth
Smoke from wildland-urban interface fires more deadly than remote wildfires
What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood
Protein accidentally lassos itself, helping explain unusual refolding behavior
With bird flu in raw milk, many in U.S. still do not know risks of consuming it
University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease
UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS
Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it
A closer look at biomolecular ‘silly putty’
Oxytocin system of breastfeeding affected in mothers with postnatal depression
Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles
[Press-News.org] Ruxolitinib for myelofibrosis: Indication of considerable added benefitAdvantages in symptoms and survival time in comparison with 'best supportive care'